腫瘤科(兒科)
免疫治療
Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. (開啟新視窗)
來源: N Engl J Med 2017;376(9):836-47.
檢索: PubMed 28249141
DOI碼: 10.1056/NEJMoa1609783
Chimeric antigen receptor T cells for sustained remissions in leukemia. (開啟新視窗)
來源: N Engl J Med 2014;371(16):1507-17.
檢索: PubMed 25317870
DOI碼: 10.1056/NEJMoa1407222
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. (開啟新視窗)
來源: N Engl J Med 2018;378(5):439-48.
檢索: PubMed 29385370
DOI碼: 10.1056/NEJMoa1709866
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. (開啟新視窗)
來源: Cancer 2013;119(22):4036-43.
檢索: PubMed 24006085
DOI碼: 10.1002/cncr.28334
Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. (開啟新視窗)
來源: Clin Cancer Res 2016;22(8):1951-7.
檢索: PubMed 26644412
DOI碼: 10.1158/1078-0432.CCR-15-1349